8-K: CytoSorbents Faces FDA Setback: DrugSorb-ATR De Novo Request Denied

CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in coronary artery bypass grafting (CABG) patients.

Summary

• CytoSorbents Corporation announced that the FDA issued a denial letter for its De Novo Request for DrugSorb-ATR on April 25, 2025.
• The FDA identified remaining deficiencies that must be addressed before the device can be authorized for commercialization in the U.S.
• DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta.
• CytoSorbents has met with the FDA and will continue discussions to resolve the issues.
• If a resolution is not reached, the company plans to file a formal appeal within 60 days of receiving the denial letter.
• The company remains committed to bringing DrugSorb-ATR to market to address the unmet medical need of preventing life-threatening bleeding in CABG patients treated with Brilinta.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the FDA denial, but the company's commitment to resolving the issues and potential for appeal provide some optimism.

Positives

• CytoSorbents is actively engaging with the FDA to address the deficiencies identified in the denial letter.
• The company is committed to pursuing all available options, including a formal appeal, to bring DrugSorb-ATR to market.
• CytoSorbents believes it can resolve the remaining issues in a timely manner.
• DrugSorb-ATR has received two FDA Breakthrough Device Designations.

Negatives

• The FDA's denial of the De Novo Request for DrugSorb-ATR represents a setback for CytoSorbents.
• Commercialization of DrugSorb-ATR in the U.S. is delayed due to the identified deficiencies.
• There is no guarantee that the company will be able to resolve the remaining issues with the FDA.

Risks

• The company may not be able to resolve the remaining deficiencies identified by the FDA.
• The formal appeal may be unsuccessful.
• The commercialization of DrugSorb-ATR in the U.S. may be further delayed or prevented altogether.
• The company's financial performance could be negatively impacted by the delay in DrugSorb-ATR approval.

Future Outlook

CytoSorbents anticipates a final regulatory decision in 2025 and will continue working closely with the FDA to resolve the remaining issues.

Management Comments

• 'We remain deeply committed to bringing DrugSorb-ATR to market as an important solution to address the serious, unmet medical need of preventing life-threatening bleeding in CABG patients treated with Brilinta,' said Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• Dr. Chan stated that the company believes it can resolve the remaining issues in a timely manner.

Industry Context

The announcement highlights the challenges and regulatory hurdles faced by medical device companies seeking FDA approval for innovative technologies. The need for solutions to reduce bleeding in CABG patients treated with antiplatelet drugs remains a significant unmet medical need.

Comparison to Industry Standards

• DrugSorb-ATR aims to address a similar market as companies developing products for blood management during surgery, such as Haemonetics with its cell salvage systems and Baxter International with its hemostatic agents.
• Unlike traditional approaches, DrugSorb-ATR focuses on removing the antiplatelet drug itself, potentially offering a more targeted solution.
• The success of DrugSorb-ATR will depend on its ability to demonstrate superior efficacy and safety compared to existing blood management strategies.

Stakeholder Impact

• Shareholders may experience a negative impact due to the delay in DrugSorb-ATR approval.
• Patients may face continued risk of bleeding during CABG surgery while awaiting the availability of DrugSorb-ATR.
• Employees may experience uncertainty regarding the future of the DrugSorb-ATR program.

Next Steps

• CytoSorbents will continue interactive conversations with the FDA to resolve the remaining issues.
• If a resolution is not reached, a formal appeal will be filed within 60 days of receipt of the denial letter.

Key Dates

Keywords

DrugSorb-ATR, CytoSorbents, FDA, De Novo Request, CABG, Brilinta, Regulatory Approval, Bleeding, Cardiothoracic Surgery, Blood Purification